Sporadic medullary carcinoma of the colon: A clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma

American Journal of Clinical Pathology

Volumn 123, Issue 1, 2005, Pages 56-65

  Wick, Mark R ^a,e   Vitsky, Jon L ^b   Ritter, Jon H ^c   Swanson, Paul E ^d   Mills, Stacey E ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b ST LUKE S HOSPITAL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^e UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

Author keywords

Colorectal carcinoma; Microsatellite instability; Occult neuroendocrine differentiation; Undifferentiated carcinoma

Indexed keywords

CHROMOGRANIN; SYNAPTOPHYSIN;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY LABELING; ARTICLE; ASCENDING COLON; CANCER GRADING; CANCER INFILTRATION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER STAGING; CLINICAL FEATURE; COLON ADENOCARCINOMA; COLON CARCINOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDULLARY CARCINOMA; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; RECTUM; SEX DIFFERENCE; SIGMOID; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; AGED; CARCINOMA, MEDULLARY; CARCINOMA, NEUROENDOCRINE; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 11244258417     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/1VFJ-1C3L-P52A-4FP8     Document Type: Article

References (46)

1. Kakar S, Aksoy S, Burgart LJ, et al. Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol. 2004;17:696-700.
2. Mai KT, Isotalo PA, Guindi M, et al. Intestinal epithelial lesions associated with signet ring cell carcinoma of the colon and small intestine. Pathology. 2002;34:51-56.
3. Reyes CV, Siddiqui MT. Anaplastic carcinoma of the colon: clinicopathologic study of eight cases of a poorly recognized lesion. Ann Diagn Pathol. 1997;1:19-25.
4. Paajanen H, Heikkinen M, Tarvainen R, et al. Anaplastic colon carcinoma associated with necrotizing vasculitis. J Clin Gastroenterol. 1995;21:168-169.
5. Gould VE, Chejfec G. Neuroendocrine carcinomas of the colon: ultrastructural and biochemical evidence of their secretory function. Am J Surg Pathol. 1978;2:31-38.
6. Chejfec G, Capella C, Solcia E, et al. Amphicrine cells, dysplasias, and neoplasias. Cancer. 1985;56:2683-2690.
7. Iezzoni JC, Mills SE. Sarcomatoid carcinomas (carcinosarcomas) of the gastrointestinal tract: a review. Semin Diagn Pathol. 1993;10:176-187.
8. Frizelle FA, Hobday KS, Batts KP, et al. Adenosquamous and squamous carcinoma of the colon and upper rectum: a clinical and histopathologic study. Dis Colon Rectum. 2001;44:341-346.
9. Kon S, Kasai K, Tsuzuki N, et al. Lymphoepithelioma-like carcinoma of rectum: possible relation with EBV Pathol Res Pract. 2001;197:577-582.
10. Jessurun J, Romero-Guadarrama M, Manivel JC. Medullary adenocarcinoma of the colon: clinicopathologic study of 11 cases. Hum Pathol. 1999;30:843-848.
11. Ponz de Leon M, Di Gregorio C. Pathology of colorectal cancer. Dig Liver Dis. 2001;33:372-388.
12. Chavez-Blanco A, Taja-Chayeb L, Cetina L, et al. Neuroendocrine marker expression in cervical carcinomas of non-small-cell type. Int J Gynecol Pathol. 2002;21:368-374.
13. Indinnimeo M, Cicchini C, Memeo L, et al. Correlation between chromogranin-A expression and pathological variables in human colon carcinoma. Anticancer Res. 2002;22:395-398.
14. Foley EF, Gaffey MJ, Frierson HF Jr. The frequency and clinical significance of neuroendocrine cells within stage III adenocarcinomas of the colon. Arch Pathol Lab Med. 1998;122:912-914.
15. Syversen U, Halvorsen T, Marvik R, et al. Neuroendocrine differentiation in colorectal carcinomas. Eur J Gastroenterol Hepatol. 1995;7:667-674.
16. Kiriakogiani-Psaropoulou P, Malamou-Mitsi V, Martinopoulou U, et al. The value of neuroendocrine markers in non-small cell lung cancer: a comparative immunohistopathologic study. Lung Cancer. 1994;11:353-364.
17. Lapertosa G, Baracchini P, Delucchi F. Prevalence and prognostic significance of endocrine cells in colorectal adenocarcinomas. Pathologica. 1994;86:170-173.
18. Park JG, Choe GY, Helman LJ, et al. Chromogranin-A expression in gastric and colon cancer tissues. Int J Cancer. 1992;51:189-194.
19. Staren ED, Could VE, Jansson DS, et al. Neuroendocrine differentiation in "poorly differentiated" colon carcinomas. Am Surg. 1990;56:412-419.
20. Helman LJ, Gazdar AF, Park JG, et al. Chromogranin-A expression in normal and malignant human tissues. J Clin Invest. 1988;82:686-690.
21. Lauriola L, Erlandson RA, Rosai J. Neuroendocrine differentiation is a common feature of thymic carcinoma. Am J Surg Pathol. 1998;22:1059-1066.
22. True L. Why we must better understand neuroendocrine differentiation in prostate cancer [editorial]. J Urol. 2004;171:443-444.
23. Hinoi T, Tani M, Lucas PC, et al. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol. 2001;159:2239-2248.
24. Greene FL. TNM staging for malignancies of the digestive tract. Semin Surg Oncol. 2003;21:23-29.
25. Imam SA, Young L, Chaiwun B, et al. Comparison of two microwave-based antigen-retrieval solutions in unmasking epitopes in formalin-fixed tissue for immunostaining. Anticancer Res. 1995;15:1153-1158.
26. Cerilli LA, Ritter JH, Mills SE, et al. Neuroendocrine neoplasms of the lung. Am J Clin Pathol. 2001;116 (suppl):S65-S96.
27. Tisserand P, Fouquet C, Barrois M, et al. Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors. Cancer Biol Ther. 2003;2:559-563.
28. Lee SC, Berg KD, Sherman ME, et al. Microsatellite instability is infrequent in medullary breast cancer. Am J Clin Pathol. 2001;115:823-827.
29. Marques AR, Catarino AL, Moniz S, et al. Medullary carcinomas of the thyroid: a monoclonal origin. Thyroid. 2001;11:1109-1113.
30. Gaffey MJ, Mills SE, Lack EE. Neuroendocrine carcinoma of the colon and rectum: a clinicopathologic, ultrastructural, and immunohistochemical study of 24 cases. Am J Surg Pathol. 1990;14:1010-1023.
31. Sarsfield P, Anthony PP. Small-cell undifferentiated (neuroendocrine) carcinoma of the colon. Histopathology. 1990;16:357-363.
32. Staren ED, Gould VE, Warren WH, et al. Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation. Surgery. 1988;104:1080-1089.
33. Sigel JE, Goldblum JR. Neuroendocrine neoplasms arising in inflammatory bowel disease: a report of 14 cases. Mod Pathol. 1998;11:537-542.
34. Saclarides TJ, Szeluga D, Staren ED. Neuroendocrine cancers of the colon and rectum: results of a ten-year experience. Dis Colon Rectum. 1994;37:635-642.
35. Bernick PE, Klimstra DS, Shia J, et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum. 2004;47:163-169.
36. Grabowski P, Schonfelder J, Ahnert-Hilger G, et al. Expression of neuroendocrine markers: a signature of human undifferentiated carcinoma of the colon and rectum. Virchows Arch. 2002;441:256-263.
37. Wick MR, Weatherby RP, Weiland LH. Small-cell neuroendocrine carcinoma of the colon and rectum: clinical, histologic, and ultrastructural study, and immunohistochemical comparison with cloacogenic carcinoma. Hum Pathol. 1987;18:9-21.
38. Mills SE, Allen MS Jr, Cohen AR. Small-cell undifferentiated carcinoma of the colon: a clinicopathological study of five cases and their association with colonic adenomas. Am J Surg Pathol. 1983;7:643-651.
39. Alexander J, Watanabe T, Wu TT, et al. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158:527-535.
40. Parc Y, Gueroult S, Mourra N, et al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut. 2004;53:371-375.
41. Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer. 2001;1:104-109.
42. Perrin J, Gouvernet J, Parriaux D, et al. MSH2 and MLH1 immunodetection and the prognosis of colon cancer. Int J Oncol. 2001;19:891-895.
43. Elsaleh H, Powell B, Soontrapornchai P, et al. p53 gene mutation, microsatellite instability, and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology. 2000;58:52-59.
44. Lleonart ME, Garcia-Foncillas J, Sanchez-Prieto R, et al. Microsatellite instability and p53 mutations in sporadic right and left colon carcinoma: different clinical and molecular implications. Cancer. 1998;83:889-895.
45. Forster S, Sattler HP, Hack M, et al. Microsatellite instability in sporadic carcinomas of the proximal colon: association with diploid DNA content, negative protein expression of p53, and distinct histomorphologic features. Surgery. 1998;123:13-18.
46. Samowitz WS, Holden JA, Curtin K, et al. Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol. 2001;158:1517-1524.